SNGX
NASD Soligenix, Inc.$0.3517 ↑ +0.0000 (+0.00%) Trading Up from the previous close of $0.3517, $0.0178 below the day’s high of $0.3695
- YTD change
- -73.75%
- vs 20-day SMA
- -4.34%
- vs 200-day SMA
- -53.64%
Price ranges
Price & Performance
-0.80 (-69.42%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 100.0% away from all-time highs of $1,955.7600
- SNGX is down 74% since the beginning of the year
- SNGX is down 79% over the past 12 months
- SNGX is down 3% over the past 1 month
- 1% of all SNGX investors are betting against SNGX
SNGX reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -79.6%.
- Previous minute
- +$0.0000
- Last hour
- +$0.0000
- Last 5 days
- -3.75%
- vs 8-day SMA
- -2.03%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
